Compare Novartis AG (NVS) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Wolfspeed Inc — how do they compare? Novartis AG trades at $143.32 (market cap $268.57B), while Wolfspeed Inc trades at $30.02 (market cap $1.64B). The key difference: Novartis AG is far larger — about 163.8× Wolfspeed Inc's market cap, and Novartis AG pays a 3.31% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Wolfspeed Inc for 19 Days on average.
| NVS | WOLF | |
|---|---|---|
Market Cap | $268.57B | $1.64B |
Volume | 1,532,573 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $168.62 | $73.68 |
52-Week Low | $121.80 | $14.80 |
Typical Hold Time | 82 Days | 19 Days |
Enterprise Value | $309.89B | $2.35B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Wolfspeed (WOLF) trades at $31.23, down 0.45% on the day, with a bullish technical signal driven by moving averages. The company reported a significant net loss of -$1.61B in 2025, with negative gross and net profit margins, though 2026 projections show potential for a small profit. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI infrastructure sector.
The outlook is mixed; analyst consensus is a Buy with a $54.32 price target, suggesting substantial upside, but high execution risk remains due to persistent losses and ongoing legal investigations. Revenue growth and achieving profitability are critical for stock performance, with the transition to 800-volt AI data centers being a potential catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
